Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00848198 · ClinicalTrials.gov registry record
TearLab Core Validation Study to Establish Referent Values for Dry Eye Disease
A clinical trial of Keratoconjunctivitis Sicca, sponsored by TearLab Corporation.
- Completed
- Registry status
- 314
- Enrollment target
- 10
- Study locations
NCT00848198 is a study of Keratoconjunctivitis Sicca that has completed, run by TearLab Corporation. The registered enrollment target is 314 participants, above the 137-participant average among 9 other Keratoconjunctivitis Sicca trials with a reported enrollment target (129% higher). The trial reports 10 study locations across 7 states.
The verdict
NCT00848198, a study of Keratoconjunctivitis Sicca, has completed, sponsored by TearLab Corporation.
- COMPLETED
- Registry status
- 314 participants
- Enrollment target
- 10
- Study locations
Study Summary
This is a prospective, observational case series to determine the clinical utility of tear osmolarity and other commonly used objective tests to diagnose dry eye disease, as well as to establish referent values for objective tests of the disease.
Conditions Studied
Study Locations (10)
Other
- Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts - Paris
- University of Wurzburg - Würzburg
- Hospital Clinico San Carlos - Madrid
Missouri
- Pepose Vision Institute - Chesterfield
- Tauber Eye Clinic - Kansas City
California
- Gordon Binder Weiss Vision Institute - San Diego
Kentucky
- Kentucky Lion Eye Center - Louisville
North Carolina
- Mundorf Eye Center - Charlotte
Ohio
- Ohio State University - Columbus
Scotland
- Division of Vision Sciences - Glasgow
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 314 participants |
| Start Date | 2009-02 |
| Est. Completion | 2011-03 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00848198
The ClinicalTrials.gov registry entry for NCT00848198 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 314 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 137-participant average among 9 other Keratoconjunctivitis Sicca trials with a reported enrollment target (129% higher). The listed sponsor is TearLab Corporation, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Keratoconjunctivitis Sicca appearing as the primary indexed condition, and to 0 interventions.
NCT00848198 reports 10 study locations spanning 7 distinct geographic areas - top geographies include Other, Missouri, California.
Frequently Asked Questions
What is clinical trial NCT00848198 about?
NCT00848198 is a clinical study titled "TearLab Core Validation Study to Establish Referent Values for Dry Eye Disease". This is a prospective, observational case series to determine the clinical utility of tear osmolarity and other commonly used objective tests to diagnose dry eye disease, as well as to establish referent values for objective tests of the disease.
What is the current status of trial NCT00848198?
This trial is currently completed. The enrollment target is 314 participants. The study started on 2009-02. Estimated completion is 2011-03.
What conditions does trial NCT00848198 study?
This clinical trial studies the following conditions: Keratoconjunctivitis Sicca.
Who is sponsoring clinical trial NCT00848198?
This trial is sponsored by TearLab Corporation, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00848198 being conducted?
This trial has 10 study locations across California, Kentucky, Missouri, North Carolina, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Keratoconjunctivitis Sicca
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Safety and Efficacy Study of Tavilermide (MIM-D3) Ophthalmic Solution for the Treatment of Dry Eye Disease
COMPLETED · Phase 3
-
Safety and Efficacy Study of Rebamipide 2% Ophthalmic Suspension in Patients With Dry Eye
COMPLETED · Phase 2
-
Effects of Dry Eye Treatments on the Ocular Surface
COMPLETED · Phase 4
-
Treatment of Dry Eye Syndrome With Cyclosporin A Eye Drops
COMPLETED · Phase 2
-
A Dose-Escalation Study to Assess the Safety and Tolerability of LX214 Ophthalmic Solution in Healthy Volunteers, Followed by an Open-Label Evaluation of LX214 in Patients With Keratoconjunctivitis Sicca (KCS)
COMPLETED · Phase 1
-
Dry Eye Assessment and Management: Feasibility Study
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.